Cargando…
Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19
Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250997/ https://www.ncbi.nlm.nih.gov/pubmed/35795188 http://dx.doi.org/10.3389/fcimb.2022.916012 |
_version_ | 1784739937793343488 |
---|---|
author | Hu, Xi Jia, Chen Wu, Jianyong Zhang, Jian Jiang, Zhijie Ma, Kuifen |
author_facet | Hu, Xi Jia, Chen Wu, Jianyong Zhang, Jian Jiang, Zhijie Ma, Kuifen |
author_sort | Hu, Xi |
collection | PubMed |
description | Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents via blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed. |
format | Online Article Text |
id | pubmed-9250997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92509972022-07-05 Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 Hu, Xi Jia, Chen Wu, Jianyong Zhang, Jian Jiang, Zhijie Ma, Kuifen Front Cell Infect Microbiol Cellular and Infection Microbiology Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents via blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed. Frontiers Media S.A. 2022-06-20 /pmc/articles/PMC9250997/ /pubmed/35795188 http://dx.doi.org/10.3389/fcimb.2022.916012 Text en Copyright © 2022 Hu, Jia, Wu, Zhang, Jiang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Hu, Xi Jia, Chen Wu, Jianyong Zhang, Jian Jiang, Zhijie Ma, Kuifen Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title | Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title_full | Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title_fullStr | Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title_full_unstemmed | Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title_short | Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19 |
title_sort | towards the antiviral agents and nanotechnology-enabled approaches against parvovirus b19 |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250997/ https://www.ncbi.nlm.nih.gov/pubmed/35795188 http://dx.doi.org/10.3389/fcimb.2022.916012 |
work_keys_str_mv | AT huxi towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 AT jiachen towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 AT wujianyong towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 AT zhangjian towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 AT jiangzhijie towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 AT makuifen towardstheantiviralagentsandnanotechnologyenabledapproachesagainstparvovirusb19 |